Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

NCT04865705 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Stage III
Non-small Cell Lung Cancer

Interventions

DRUG: tislelizumab

Sponsor

West China Hospital